Arca
Skip to content
Tools
Tools

Autosomal dominant polycystic kidney

Drug research and approvals for autosomal dominant polycystic kidney: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 34 studies of autosomal dominant polycystic kidney are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 1 approved and 18 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 34
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting now

Newest posted first, of 34 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 12

Phase 2 8

Phase 1 or earlier 2

How its trials ended

151 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 39 whose ending is known, 51% met their primary endpoint, 10% missed it and 38% stopped early.

  • Completed, result not reported5436%
  • Ongoing4228%
  • Met its primary endpoint2013%
  • Status unknown1611%
  • Stopped: sponsor or business decision64%
  • Missed its primary endpoint43%
  • Stopped: lack of efficacy43%
  • Stopped: other or unclear32%
  • Stopped: safety11%
  • Stopped: enrollment or feasibility11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 27, 2025A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-CLS-628 in adult subjects with autosomal…ABBV-CLS-628Calico Life Sciences LLCOngoing
Mar 19, 2025A randomised, double blind, placebo-controlled, single ascending dose, phase 1a/1b multi-centre study in healthy participants and participants with autosomal…GSK4771261GSKOngoing
Nov 2, 2021A phase 3 study of the efficacy and safety of lixivaptan in participants with autosomal dominant polycystic kidney disease consisting of a 1-year double-blind,…LixivaptanPalladio BiosciencesOngoing
Apr 9, 2021Multicenter, open-label, extension study to characterize the long-term efficacy and safety of early versus delayed treatment with venglustat (gz/SAR402671) in…Venglustat (SAR402671)Sanofi-Aventis Canada IncPending
Sep 6, 2018Multicenter, randomized, double-blind, placebo-controlled two stage study to characterize the efficacy, safety, tolerability and pharmacokinetics of…Venglustat (GZ/SAR402671)SanofiOngoing
Jun 27, 2016A pilot study of cystic volume reduction by foam sclerotherapy in autosomal dominant polycystic kidney diseaseSodium tetradecyl sulfateUniversity Health NetworkOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 19
Apr 23, 2018JynarqueJYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease…Otsuka Pharmaceutical Company, Ltd.Approved
Aug 19, 2026Eukaryotic ribosome-selective glycosideTreatment of autosomal dominant polycystic kidney diseaseEloxx PharmaceuticalsDesignated
Jul 8, 2026Human IgG1kappa monoclonal antibody that specifically binds…Treatment of autosomal dominant polycystic kidney diseaseAstraZeneca Pharmaceuticals LPDesignated
Mar 26, 2026TamibaroteneTreatment of autosomal dominant polycystic kidney diseaseRege Nephro Co., Ltd.Designated
Nov 1, 2025Fully human IgG1 monoclonal antibody that binds to human…Treatment of autosomal dominant polycystic kidney diseaseCalico Life Sciences LLCDesignated
Sep 8, 2025OctreotideTreatment of autosomal dominant polycystic kidney diseaseCamurus ABDesignated
Sep 5, 2025SalsalateTreatment of autosomal dominant polycystic kidney diseaseJ & D Pharmaceuticals LLCDesignated
Aug 29, 2025Anti-PAPPA mAbTreatment of autosomal dominant polycystic kidney disease (ADPKD)GlaxoSmithKline Research & Development LimitedDesignated
Feb 12, 2024(S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy-1…Treatment of autosomal dominant polycystic kidney disease (ADPKD)Shanghai Alebund Pharmaceuticals Ltd.Designated
Apr 20, 2023OxypurinolTreatment of autosomal dominant polycystic kidney diseaseXORTX Therapeutics Inc.Designated
Nov 22, 2022MebendazoleTreatment of Autosomal Dominant Polycystic Kidney DiseaseHealx Technology LimitedDesignated
Sep 14, 2022Potassium…Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)SCYNEXIS, Inc.Designated
Jun 16, 2022A chemically modified full phosphorothioate-backbone…Autosomal dominant polycystic kidney disease (ADPKD)Novartis Pharmaceuticals CorporationDesignated
May 26, 2021TesevatinibTreatment of autosomal dominant polycystic kidney diseaseKadmon CorporationDesignated
Jun 3, 2019Bardoxolone methylTreatment of autosomal dominant polycystic kidney diseaseReata Pharmaceuticals, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 27, 2015JinarcTolvaptanOtsuka Pharmaceutical Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.